Apellis Pharmaceuticals, INC

Apellis Pharmaceuticals has been acquired by Biogen Inc. through a merger, with convertible senior notes being modified to reflect the new ownership and terms.

Apellis Pharmaceuticals, Inc. has amended its Executive Separation Benefits and Retention Plan in anticipation of its merger with Biogen Inc., accelerating vesting for certain unvested awards upon termination under specific conditions.

Biogen Inc. will acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right of up to $4.00 per share, expanding its immunology and rare disease footprint.

Apellis Pharmaceuticals, Inc. announced the election of Mikael Dolsten, M.D., Ph.D., to its Board of Directors as a Class I director, effective March 1, 2026.

Apellis Pharmaceuticals announced preliminary 2025 U.S. net product revenues of $689 million, driven by strong SYFOVRE demand and EMPAVELI's successful launch, positioning the company for profitability.

Apellis Pharmaceuticals, Inc. entered into a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Publ), receiving an upfront payment of $275 million and reducing Sobi's future royalty obligations by 90%.

Apellis Pharmaceuticals announced strong Q1 2026 revenue growth driven by its key drugs, SYFOVRE and EMPAVELI, while progressing towards its acquisition by Biogen.

Apellis Pharmaceuticals reported a significant swing to net income in Q3 2025, driven by a $275 million upfront payment from a royalty buy-down agreement with Sobi, alongside stable SYFOVRE sales and new EMPAVELI indications.

Apellis Pharmaceuticals reported increased net losses and decreased product revenue for the second quarter and first half of 2025, but secured significant liquidity through a royalty buy-down agreement and gained a new FDA approval for EMPAVELI.

Apellis Pharmaceuticals' Q1 2025 results reveal a decrease in SYFOVRE sales due to higher rebates and EMPAVELI revenue decline due to oral competition, despite progress in clinical trials and regulatory submissions.

Apellis Pharmaceuticals' Q3 2024 results show significant revenue growth driven by Syfovre sales, alongside updates on clinical programs and financial activities.

Apellis Pharmaceuticals' second quarter results show significant revenue growth, primarily driven by increased sales of their geographic atrophy treatment, Syfovre.

Apellis Pharmaceuticals, Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include Part III information previously omitted.

Apellis Pharmaceuticals achieved its first net income of $22.4 million in 2025, driven by strong licensing revenue and continued commercialization of SYFOVRE and EMPAVELI, despite a decline in SYFOVRE sales.

Apellis Pharmaceuticals' 2024 10-K filing highlights strong revenue growth from SYFOVRE and EMPAVELI, while outlining strategic initiatives and ongoing clinical developments.

Apellis Pharmaceuticals files an amendment to its 10-K report to correct administrative errors related to audit reports and includes new certifications from its executives.

Apellis Pharmaceuticals reports significant revenue growth driven by SYFOVRE and EMPAVELI, while addressing safety concerns and strategic pipeline adjustments in its 2023 10-K filing.

Director A. Sinclair Dunlop reports the disposal of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Director Mikael Dolsten reports the disposition of all Apellis Pharmaceuticals equity holdings following the company's acquisition by Biogen.

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Director Paul Fonteyne reports the disposition of all Apellis Pharmaceuticals equity holdings following the company's acquisition by Biogen.

Apellis Pharmaceuticals has been acquired by Biogen in a transaction effective May 14, 2026, resulting in the delisting of its common stock.

Apellis Pharmaceuticals announces its annual meeting of stockholders to be held virtually on June 3, 2025, covering director elections, auditor ratification, and executive compensation votes.

Apellis Pharmaceuticals outlines its strategic achievements in 2024 and plans for 2025, focusing on expanding the market reach of EMPAVELI and SYFOVRE and advancing its pipeline.

Apellis Pharmaceuticals will hold its annual stockholders meeting on June 5, 2024, to elect directors, ratify the appointment of its auditor, and conduct an advisory vote on executive compensation.

Apellis Pharmaceuticals sets date for its 2024 annual stockholders meeting, outlining key proposals including director elections, auditor ratification, and executive compensation advisory vote.

Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger, marking an exit filing for Biogen.

Biogen Inc. announced its definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right (CVR) per share, valuing the company at approximately $41 billion.

Morgan Stanley has filed an amendment to its Schedule 13G, reporting that it no longer beneficially owns more than five percent of Apellis Pharmaceuticals common stock.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 4,532,374 shares, representing 3.55% of the outstanding common stock of Apellis Pharmaceuticals, Inc. as of March 31, 2026.

RTW Investments, LP and Roderick Wong report beneficial ownership of 3,685,045 shares, representing 2.9% of Apellis Pharmaceuticals, Inc. common stock.

State Street Corporation has reported beneficial ownership of 5.4% of Apellis Pharmaceuticals Inc. common stock as of March 31, 2026.

Wellington Management Group has reduced its stake in Apellis Pharmaceuticals to 0.2%, signaling a significant divestment by the institutional giant.

The Vanguard Group reported a 0% beneficial ownership in Apellis Pharmaceuticals Inc. common stock following an internal corporate realignment.